Cancer patients at Penn Medicine now benefit from the most advanced Imaging Guided Proton Therapy (IGPT)

Philadelphia, United States - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, and Université Catholique de Louvain announced today that the first patient treatment with IBA's Proton Therapy Specific Cone Beam CT (CBCT) was successfully completed at Penn Medicine's Roberts Proton Therapy Center.

As a component of IBA's Image Guided Proton Therapy (IGPT) solution, CBCT provides 3D imaging for increased accuracy in patient treatment. It is fully integrated with IBA's imaging platform adaPTinsight*, developed in partnership with the Université catholique de Louvain (UCL), to offer fast 6D corrections of patient positioning for IBA's Proteus®PLUS** and Proteus®ONE*** proton therapy solutions.
Dr. James M. Metz, MD, Professor and Vice Chair, Radiation Oncology, Penn Medicine commented: "We are very excited to be the first proton therapy center in the world to provide the CBCT 3D imaging solution. CBCT is a great tool for highly accurate patient positioning. It also enables the clinicians to assess the patient anatomical change over the treatment course regularly and to adapt the treatment plan whenever needed. The end results significantly benefit the patients, with enhanced precision and accuracy of the proton therapy delivery. We believe that this is another significant step in improving our ability to help patients achieve their goals of beating their cancer with as few side effects as possible."

Olivier Legrain, Chief Executive Officer of IBA commented: "We are very proud to be the first company in the world to provide the clinical proton therapy specific CBCT solution. The development of imaging capabilities is critical to the expansion of the use of proton therapy in new cancer indications and IBA has developed advanced radiation therapy solutions that improve the overall treatment experience for both clinicians and patients. CBCT is just one example of the latest technological advancements achieved by IBA that support our unrivalled position as the world's leader in the innovation and delivery of proton therapy."

Frederic Genin, Executive VP Product Management at IBA added: "IBA's significant experience and successful collaborations with key users make it possible to achieve this important milestone in the development of specific imaging solutions for proton therapy. The applications of image guidance and image monitoring are of paramount importance to benefit from the superior dose distribution of proton therapy. By adding Cone Beam CT as one of IBA's Image Guided Proton Therapy solutions, we are accelerating the development of Adaptive Proton Therapy."

More HCB News